Compare Stocks → Grab Your Free Bitcoin Today! (From Crypto Swap Profits) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALTNASDAQ:TERN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$10.18+14.5%$9.90$2.09▼$14.84$546.97M0.086.07 million shs8.49 million shsTERNTerns Pharmaceuticals$6.56+6.5%$6.64$3.26▼$14.04$424.12M-0.61840,073 shs1.23 million shs(Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune+14.51%+11.75%-26.29%-9.51%+132.95%TERNTerns Pharmaceuticals+6.49%+0.15%-17.90%+1.08%-45.33%Altcoin FRENZY Alert… (Ad)Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… Click here now to register for the event (FOR FREE!)MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTAltimmune1.3232 of 5 stars3.42.00.00.02.11.70.0TERNTerns Pharmaceuticals3.8687 of 5 stars3.42.00.04.12.42.50.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune2.75Moderate Buy$15.7554.72% UpsideTERNTerns Pharmaceuticals2.75Moderate Buy$14.94127.71% UpsideCurrent Analyst RatingsLatest ALT, TERN, ADA, and DTS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2024ALTAltimmuneB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.003/27/2024TERNTerns PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$19.00 ➝ $18.003/18/2024TERNTerns PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$17.00 ➝ $15.003/15/2024TERNTerns PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$5.503/15/2024TERNTerns PharmaceuticalsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$18.00 ➝ $19.002/13/2024ALTAltimmuneB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.001/24/2024ALTAltimmuneThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$13.001/10/2024TERNTerns PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$8.00 ➝ $5.50(Data available from 3/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$4.41M124.03N/AN/A$3.77 per share2.70TERNTerns Pharmaceuticals$1M424.12N/AN/A$4.13 per share1.59Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$84.71M-$1.54N/AN/AN/AN/A-46.81%-42.23%5/9/2024 (Estimated)TERNTerns Pharmaceuticals-$90.21M-$1.27N/AN/AN/AN/A-33.55%-31.90%5/20/2024 (Estimated)Latest ALT, TERN, ADA, and DTS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/14/2024Q4 2023TERNTerns Pharmaceuticals-$0.29-$0.29N/A-$0.29N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/ATERNTerns PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmuneN/A12.8912.89TERNTerns PharmaceuticalsN/A22.3922.39OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%TERNTerns Pharmaceuticals98.26%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.10%TERNTerns Pharmaceuticals17.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5253.73 million51.53 millionOptionableTERNTerns Pharmaceuticals6664.65 million53.40 millionNot OptionableALT, TERN, ADA, and DTS HeadlinesSourceHeadlineThis small-cap stock is expected to take off — if its weight-loss pill trial succeedsmarketwatch.com - March 28 at 3:24 PMTerns Pharmaceuticals (NASDAQ:TERN) Given New $18.00 Price Target at UBS Groupamericanbankingnews.com - March 28 at 3:58 AMUBS Group Lowers Terns Pharmaceuticals (NASDAQ:TERN) Price Target to $18.00marketbeat.com - March 27 at 3:09 PMHere’s Why Ozempic And Mounjaro Rivals Won’t Topple Weight Loss Drugmakers Novo Nordisk And Eli Lilly Anytime Soonmsn.com - March 27 at 9:31 AMWall Street's Favorite Biotech Stocks? 3 Names That Could Make You Filthy Richinvestorplace.com - March 25 at 3:00 PMOptimistic Buy Rating for Terns Pharmaceuticals Based on Strong Clinical Pipeline and Financial Stabilitymarkets.businessinsider.com - March 21 at 6:49 AMTerns Pharmaceuticals (NASDAQ:TERN) Given New $15.00 Price Target at JMP Securitiesamericanbankingnews.com - March 19 at 4:54 AMBMO Capital Markets Increases Terns Pharmaceuticals (NASDAQ:TERN) Price Target to $19.00americanbankingnews.com - March 19 at 2:48 AMTerns Pharmaceuticals' (TERN) "Neutral" Rating Reiterated at HC Wainwrightamericanbankingnews.com - March 19 at 2:48 AMHC Wainwright Reaffirms "Neutral" Rating for Terns Pharmaceuticals (NASDAQ:TERN)marketbeat.com - March 18 at 6:33 PMTerns Pharmaceuticals (NASDAQ:TERN) PT Raised to $19.00marketbeat.com - March 18 at 6:33 PMTerns Pharmaceuticals (NASDAQ:TERN) PT Lowered to $15.00marketbeat.com - March 18 at 5:31 PMTERN Apr 2024 15.000 callfinance.yahoo.com - March 16 at 1:45 PMTerns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updatesglobenewswire.com - March 14 at 4:05 PMTerns Pharmaceuticals, Inc.: Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemiafinanznachrichten.de - March 12 at 4:18 AMTerns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemiaglobenewswire.com - March 11 at 4:05 PMTerns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)globenewswire.com - March 7 at 4:05 PMFmr LLC Sells 1,932,296 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN)marketbeat.com - March 4 at 5:19 AMAcuta Capital Partners LLC Lowers Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)marketbeat.com - March 3 at 12:18 PMTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Holdings Lifted by Braidwell LPmarketbeat.com - March 1 at 10:18 AMBarclays PLC Decreases Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)marketbeat.com - February 29 at 4:16 AMTerns Pharmaceuticals to Participate in Upcoming March Investor Conferencesglobenewswire.com - February 27 at 4:05 PMTerns Pharmaceuticals, Inc.: Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4)finanznachrichten.de - February 9 at 9:57 AMTerns Pharmaceuticals, Inc.: Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive Officerfinanznachrichten.de - February 7 at 5:40 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines5 Under-the-Radar Artificial Intelligence (AI) Stocks March 4, 2024 9:30 AMView 5 Under-the-Radar Artificial Intelligence (AI) Stocks Cathie Wood Likes UiPath Stock Over NVDA, Should You?March 5, 2024 7:00 AMView Cathie Wood Likes UiPath Stock Over NVDA, Should You?3 Stocks With Unusual Call Option ActivityMarch 26, 2024 1:10 PMView 3 Stocks With Unusual Call Option ActivityIs UnitedHealth Group Stock a Strong Buy or a Falling Knife?March 5, 2024 7:08 AMView Is UnitedHealth Group Stock a Strong Buy or a Falling Knife?The Ozempic Diet Trend is Lifting These 2 Carnivore StocksMarch 4, 2024 6:28 AMView The Ozempic Diet Trend is Lifting These 2 Carnivore StocksAll Headlines Company DescriptionsAltimmuneNASDAQ:ALTAltimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Terns PharmaceuticalsNASDAQ:TERNTerns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.